Date: 2014-09-17
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the 2014 Congress of the European Society for Medical Oncology (ESMO)
Company: Eisai (Japan)
Product: lenvatinib
Action
mechanism: tyrosine kinase inhibitor. Lenvatinib mesylate is an oral multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor receptors (VEGFR), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor receptors (FGFR), the platelet-derived growth factor (PDGF) receptor PDGFR?, KIT and RET that are involved in tumour proliferation. This potentially makes lenvatinib a first-in-class treatment, especially given that it simultaneously inhibits the kinase activities of FGFR as well as VEGFR. It is currently under investigation as a treatment for thyroid, hepatocellular carcinoma (Phase III), non-small cell lung cancer (Phase II) and other solid tumour types.
Disease: radioiodine-refractory differentiated thyroid cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On September 17, 2014, Eisai announced that nine abstracts for Eisai's oncology portfolio are to be presented during the European Society for Medical Oncology (ESMO) 2014 Congress, inMadrid, Spain between 26 and 30 September, 2014. Lenvatinib Phase II study of lenvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with all histologic (E7080) subtypes of advanced thyroid cancer (differentiated, medullary and anaplastic). Abstract No:995PD Poster Discussion session Lenvatinib Subgroup analyses of a phase III, multicenter,double-blind, placebo controlled trial of lenvatinib(E7080) (E7080) in patients with 131I-refractory differentiatedthyroid cancer.Abstract No: Lenvatinib Treatment-emergent hypertension and efficacy in the(E7080) phase III Study of (E7080) LEnvatinib in differentiated Cancer of the Thyroid (SELECT). Abstract No: 1030P Poster Display Session Lenvatinib Characterisation of tumour size changes over time from (E7080) the phase III Study of (E7080) LEnvatinib in differentiated Cancer of the Thyroid (SELECT). Abstract No: 1031P Poster Display Session
Data to be presented include five abstracts for lenvatinib, an investigational agent being evaluated for the treatment of progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC), will be presented. Lenvatinib received accelerated European Medicines Agency (EMA) review on the 31 July and was filed in Europeand the U.S. on 18 August 2014. Lenvatinib was filed in Japan in June 2014. Lenvatinib was granted orphan drug designation (ODD) for the treatment of follicular and papillary thyroid cancer by the European Commission in April 2013. It has ODD for follicular, medullary, anaplastic and metastatic or locally advanced papillary thyroid cancer in the U.S. and thyroid cancer in Japan.
Lenvatinib Comprehensive analysis of serum biomarker and tumour gene mutation associated with clinical outcomes in the (E7080) phase III Study of (E7080) LEnvatinib in differentiated Cancer of the Thyroid (SELECT). Abstract No: LBA30 Proferred Paper Session
1033P Poster Display Session
